4,301 Shares in PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Bought by FSM Wealth Advisors LLC

FSM Wealth Advisors LLC bought a new stake in PROCEPT BioRobotics Corporation (NASDAQ:PRCT - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 4,301 shares of the company's stock, valued at approximately $251,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. FMR LLC increased its holdings in shares of PROCEPT BioRobotics by 11.9% in the 4th quarter. FMR LLC now owns 8,159,208 shares of the company's stock valued at $656,979,000 after acquiring an additional 866,328 shares during the last quarter. Vanguard Group Inc. grew its position in PROCEPT BioRobotics by 6.1% during the 4th quarter. Vanguard Group Inc. now owns 5,140,426 shares of the company's stock worth $413,907,000 after purchasing an additional 297,075 shares during the last quarter. Alliancebernstein L.P. boosted its stake in shares of PROCEPT BioRobotics by 14.2% during the fourth quarter. Alliancebernstein L.P. now owns 1,752,478 shares of the company's stock worth $141,110,000 after buying an additional 218,148 shares during the period. Wellington Management Group LLP grew its holdings in shares of PROCEPT BioRobotics by 38.8% during the fourth quarter. Wellington Management Group LLP now owns 1,490,952 shares of the company's stock worth $120,051,000 after buying an additional 416,819 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of PROCEPT BioRobotics by 5.2% in the 4th quarter. Geode Capital Management LLC now owns 1,164,037 shares of the company's stock valued at $93,751,000 after purchasing an additional 57,449 shares during the last quarter. 89.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at PROCEPT BioRobotics

In related news, Director Antal Rohit Desai sold 25,000 shares of the firm's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $61.49, for a total transaction of $1,537,250.00. Following the sale, the director owned 14,363 shares of the company's stock, valued at $883,180.87. This trade represents a 63.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 100,000 shares of company stock valued at $6,271,250. Company insiders own 6.60% of the company's stock.

Analysts Set New Price Targets

PRCT has been the subject of several recent analyst reports. Truist Financial reduced their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a research note on Friday, April 11th. Bank of America reduced their price target on PROCEPT BioRobotics from $104.00 to $84.00 and set a "buy" rating on the stock in a research note on Friday, April 25th. Finally, Wall Street Zen upgraded PROCEPT BioRobotics from a "sell" rating to a "hold" rating in a report on Saturday, May 24th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics currently has an average rating of "Moderate Buy" and a consensus target price of $90.00.

PROCEPT BioRobotics Stock Up 1.4%

NASDAQ PRCT traded up $0.82 during trading on Friday, hitting $59.00. The stock had a trading volume of 229,134 shares, compared to its average volume of 841,342. The company has a market capitalization of $3.26 billion, a PE ratio of -34.71 and a beta of 1.07. PROCEPT BioRobotics Corporation has a 12 month low of $47.04 and a 12 month high of $103.81. The company's 50-day moving average price is $57.84 and its two-hundred day moving average price is $63.92. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.75 and a current ratio of 8.95.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.04. PROCEPT BioRobotics had a negative net margin of 36.20% and a negative return on equity of 28.09%. The firm had revenue of $69.16 million during the quarter, compared to analysts' expectations of $65.39 million. During the same period in the previous year, the business posted ($0.51) earnings per share. The company's revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, sell-side analysts forecast that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).